The Field Execution Intelligence playbook for pharma field force operations in India

A vertical playbook for India's $65B pharma sector and its 600,000+ medical representatives. Built for Sales Excellence heads, Field Force Operations leaders, and pharma CXOs running doctor coverage, chemist engagement, sample distribution, and prescription conversion across India.

G
gOGig Editorial
··12 min read

30 to 40%

Visit adherence rate observed across mid-tier Indian pharma field forces. The gap between planned doctor calls and actually completed visits is the single largest hidden cost line in Indian pharma sales operations.

$65B+India pharma market 2024
$130BProjected 2030
600,000+Medical Representatives
1.2M+Doctors targeted nationally

A National Sales Manager at a top-10 Indian pharma company opens Monday's regional review. 14,200 doctor calls reported last week. The dashboard shows 96% MTP adherence. Prescription audit data from chemists tells a different story. Coverage in three high-potential territories looks identical to coverage in low-priority pockets. The reported numbers and the ground reality are no longer reconciling.

The Indian pharma field execution map

Operational layerIndia scaleVerification maturity
Medical Representatives (MRs)600,000+Low (DCR-based self-report)
Area Business Managers / First Line Managers55,000 to 70,000Low (review-cycle dependent)
Regional Sales Managers8,000 to 12,000Medium
Doctors (target HCPs)1.2 million+Medium (master data quality varies)
Specialist doctors (priority targets)320,000 to 400,000Higher (focused coverage)
Retail chemists900,000+Low
Hospitals (private and government)69,000+Medium
Distributors / stockists65,000+Medium (DMS-driven)
Sample stock units (per company per quarter)5 to 50 millionLow (distribution unverified)
Daily Call Reports submitted nationally~5 million per dayLow (self-reported)

Daily activity benchmarks for an average MR

ActivityTypical daily targetActual baseline
Doctor calls per day10 to 146 to 9 verified
Chemist visits per day5 to 83 to 5 verified
Stockist visits per week2 to 41 to 3
Average call duration with doctor5 to 8 minutes2 to 4 minutes
RCPA conducted per week3 to 51 to 2
Sample packs distributed per week40 to 80Reported high, verified low
e-detailing sessions per week15 to 258 to 14
POB transactions per month30 to 60Variable by territory

The 5-layer FEI stack for pharma field force

1

Territory and visit verification

Geo-fenced clinic and chemist verification, EXIF preserved capture, sensor cross-check confirming actual presence, MTP adherence tracking. Replaces self-reported DCR with verified call records.

2

Authenticity and anti-spoofing

9-layer mock-location detection, face match selfie at clinic entry, duplicate visit flagging, batch submission detection. Catches geo-spoofed check-ins and shared-device fraud.

3

Prescription correlation intelligence

Links MR visits, sample drops, RCPA findings, and chemist engagement with prescription lift per doctor, per territory, per molecule. Converts activity data into commercial signal.

4

Compliance and audit infrastructure

UCPMP-aligned audit trails, content compliance logging, sample reconciliation, regulatory documentation retention. The regulatory layer for a sector under MCI, NPPA, CDSCO, and DPCO scrutiny.

5

Sales Excellence and CFO accountability

Verified call rate as KPI, productive call effectiveness, vendor scorecards, BRSR Core ready audit trail. Brings pharma field spend to procurement-grade governance.

10 pharma-specific field execution fraud patterns

Ghost doctor calls

MR marks doctor as visited without entering clinic. Sensor cross-check and door-side geo-fence catch the gap.

Pattern 01

Pattern

Batch end-of-day DCR filing

All 12 doctor calls logged between 6 to 8 PM from one location. Continuous capture exposes the timing pattern.

Pattern 02

Pattern

Mock-location DCR

MR submits DCR from home using fake GPS apps. 9-layer detection catches 99%+ of attempts.

Pattern 03

Pattern

Proxy chemist visits

Single MR check-in covers multiple chemists in same complex without actual entry. Per-shop boundary verification surfaces the issue.

Pattern 04

Pattern

Fake doctor master data

Non-existent doctors added to coverage lists for inflated call counts. OTP plus MCI registration cross-check eliminates the path.

Pattern 05

Pattern

Sample distribution unverified

Samples billed as distributed are routed elsewhere. Outlet-level sample drop reconciliation closes the loop.

Pattern 06

Pattern

Call duration inflation

2-minute corridor conversations logged as 8-minute detailing sessions. Continuous timer with location lock verifies duration.

Pattern 07

Pattern

Territory boundary violation

MR poaches doctors from neighboring territories for personal targets. Territory geo-fence flags the cross-over.

Pattern 08

Pattern

RCPA fabrication

Retail Chemist Prescription Audit numbers invented without actual audit. Photo evidence requirement plus chemist OTP catches it.

Pattern 09

Pattern

POB inflation in low-season

Prescription Order Booking numbers spike in low-season to clear targets. Stockist reconciliation surfaces the disconnect.

Pattern 10

Pattern

DCR integrity: the operational gap

The gap between reported and verified field activity is the single largest unmeasured cost line in Indian pharma sales operations. It manifests as lower prescription lift per ₹ of field spend, not as a missing expense.

DCR integrity dimensionSelf-reported baselineFEI-verified baseline
MTP adherence (% of planned calls completed)88 to 96%62 to 78%
Productive call rate72 to 84%52 to 68%
High-potential doctor coverage85 to 92%64 to 76%
Average call duration6 to 8 minutes2.5 to 4 minutes
RCPA accuracySelf-reported 100%Verified at 68 to 80%
Sample distribution accuracy95 to 99% claimed72 to 84% verified
Territory route adherence82 to 90%68 to 80%
Real-time DCR submissionReported real-time~38% submitted within 2 hours of visit

Doctor coverage architecture: A, B, C, D classification

Doctor tierDefinitionTarget call frequencyActual coverage gap
A (top potential)Top 10% prescribers in territory4 to 6 calls/month22 to 32% under-coverage
B (high potential)Next 20% prescribers2 to 3 calls/month18 to 26%
C (medium potential)Next 40% prescribers1 to 2 calls/month14 to 22%
D (low potential)Bottom 30%Quarterly or skipOften over-covered

The hidden mis-allocation in pharma field force

Allocation patternReported intentActual ground reality
A-grade doctor focus70 to 80% of MR time45 to 58%
B-grade doctor focus15 to 22%20 to 25%
C-grade doctor focus5 to 10%15 to 20%
D-grade doctor focus0 to 3%7 to 12%
Effective high-potential territory coverage92%+ claimed64 to 76% verified

Territory leakage exposure across pharma categories

Therapy areaField force size (typical large brand)Annual field operating costLeakage exposure
Cardiac and metabolic1,200 to 2,500 MRs₹120 to 280 Cr₹18 to 50 Cr
Diabetic800 to 1,800 MRs₹85 to 190 Cr₹13 to 35 Cr
Anti-infective1,500 to 3,000 MRs₹150 to 320 Cr₹22 to 60 Cr
Gastro600 to 1,400 MRs₹65 to 140 Cr₹10 to 26 Cr
Oncology200 to 600 MRs (specialist)₹30 to 80 Cr₹3 to 12 Cr
CNS / neuro400 to 1,000 MRs₹40 to 100 Cr₹6 to 18 Cr
Gynecology500 to 1,200 MRs₹55 to 130 Cr₹8 to 25 Cr
Pediatric400 to 900 MRs₹40 to 95 Cr₹6 to 18 Cr
Dermatology300 to 700 MRs₹30 to 75 Cr₹4 to 14 Cr
Ortho and pain500 to 1,100 MRs₹50 to 110 Cr₹7 to 20 Cr

Sample management: a hidden 8 to 12% leakage line

Sample lifecycle stageCommon failureFEI verification
Sample stock issuance to MRStock issued without doctor mappingAllocation linked to doctor master
Sample carry to clinicSamples sold in grey marketPer-doctor distribution log with timestamp
Sample drop at doctorSelf-reported without proofDoctor signature plus selfie capture
Sample reconciliationQuarterly review onlyReal-time MR-level sample balance
Expiry managementExpired samples in circulationBatch and expiry tracking per MR
Audit committee disclosureCannot substantiatePer-sample chain of custody
Regulatory compliance (sample restriction)Self-attestation onlyUCPMP-aligned audit trail
Promotional spend correlationTreated as separate ledgerLinked with prescription correlation data

See actual field coverage vs reported coverage

Bring one division or one therapy team for a 14-day pilot. We deploy the 5-layer FEI stack passively. You receive a verified DCR audit, territory coverage gap report, and sample reconciliation summary. Free, no setup required for M₹

Request a pharma coverage audit

RCPA intelligence: from audit to insight

RCPA practicePre-FEI workflowFEI workflow
FrequencyWeekly self-reportedWeekly verified at chemist
Photo evidenceOptional / inconsistentPrescription pad photo with chemist OTP
Competitor visibilityAnecdotal mentionsSKU-level facing count
Brand share movementQuarterly reviewWeekly trend per molecule
Chemist credibility scoringNoneChemist-level audit reliability score
Cross-territory comparisonManual collationReal-time benchmarking
Action loop closureVerbal in monthly reviewAuto-task to ABM for high-variance accounts
Audit-grade documentationExcel sheets7-year structured retention

Prescription correlation: linking activity to outcome

Activity signalOutcome metricCorrelation enabled by FEI
Verified doctor calls per monthPrescriptions per doctorPer-doctor call-to-Rx coefficient
Sample drops per doctorTrial Rx volumeSample-to-trial conversion rate
Detailing call durationBrand share movementEffective call quality score
RCPA findingsTerritory share trendAudit-derived growth signal
Chemist engagementPOB and secondary salesPull-through effectiveness
Coverage frequency by tierTier-wise Rx growthAllocation effectiveness
Speciality focus timeSpeciality-specific RxChannel productivity
New doctor onboardingFirst Rx within 60 daysOnboarding ROI

Sales Excellence KPI scorecard for pharma operations

SFE KPIPre-FEI baselineFEI-enabled target
Verified MTP adherence62 to 78%88 to 94%
Productive call rate52 to 68%72 to 85%
A-grade doctor coverage64 to 76%88 to 95%
Average call duration2.5 to 4 minutes5 to 7 minutes
Real-time DCR submission rate38%88 to 94%
Sample distribution accuracy72 to 84%94 to 98%
RCPA accuracy68 to 80%92 to 96%
Territory route adherence68 to 80%88 to 94%
MR attrition28 to 42% annual20 to 30%
Per-MR productive selling time3.5 to 4.5 hours5.5 to 6.5 hours

Compliance and regulatory layer

Regulatory frameworkImplication for pharma field force
UCPMP (Uniform Code for Pharmaceutical Marketing Practices)Sample distribution limits, promotional gifts ban, content discipline
NMC / MCI guidelines for HCP engagementDocumentation of all doctor interactions
NPPA pricing oversightPrice compliance at chemist level
CDSCO drug controlSample tracking and batch traceability
DPCO scheduled drug complianceDistribution and inventory verification
SEBI BRSR Core (listed pharma)Value chain disclosure for vendor and field force
Companies Act 2013 IFCInternal financial controls over field force spend
FCPA and UK Bribery Act (exporters)Verified compliance evidence for global listing

FEI compliance deliverables

Compliance deliverableFEI output
Per-call audit logMR, doctor, time, duration, materials shared
Sample chain of custodyPer-pack tracking from stock to drop
Promotional content disciplinee-detailing content version log
UCPMP self-attestation evidenceQuarterly verified compliance scorecards
Audit committee finding closureSubstantiable evidence for IFC findings
BRSR Core value chain disclosureField force and vendor verified records
Anti-bribery and corruption documentationDoctor engagement audit-grade trail
External auditor support7-year retained evidence accessible on demand

Field force allocation rebalancing: the Kearney lever

Reallocation scenarioCurrent statePost-rebalancing
MR count in low-productivity territories22 to 30% of force10 to 15%
MR count in high-potential territories50 to 60%65 to 75%
Average sales per MR per quarter₹18 to 32 lakh₹26 to 45 lakh
High-potential doctor coverage64 to 76%88 to 95%
MR attrition in over-allocated regions32 to 42%22 to 28%
Field force ROI2.2 to 3.5x3.5 to 5.5x

e-detailing and digital engagement

e-detailing capabilityFEI integration point
Tablet-based product detailingSession log with timestamp and duration
Doctor engagement scoringSlide-by-slide interaction logged
Content version controlAlways-current MR-approved content
Compliance-locked contentUCPMP-aligned versions only
Follow-up triggersAuto-task generated post detailing
Hybrid in-person plus digitalCross-channel doctor engagement view
Multi-language content deliveryRegional language and accent support
e-prescribing platform integrationDirect prescription correlation

Real-time decision infrastructure for pharma SFE

Decision pointPre-FEI cadenceFEI cadence
Territory rebalancingAnnualQuarterly
MR performance interventionMonthly reviewWeekly anomaly inbox
Doctor coverage gap detectionQuarterlyReal-time dashboard
Sample distribution adjustmentQuarterlyWeekly
RCPA-driven brand strategyHalf-yearlyMonthly
Field force expansion or contractionAnnual budgetingQuarterly with verified ROI data
POB scheme effectivenessQuarterlyWeekly
Compliance audit responseReactiveContinuous monitoring

Sample ROI math for a mid-sized pharma company

Line itemPre-FEIYear 1 of FEI
Field force size2,400 MRs2,400 MRs
Annual field operating cost₹280 Cr₹280 Cr
Unverified or unproductive share26%11%
Recovered productive capacity--₹42 Cr equivalent
A-grade doctor coverage uplift--+22 percentage points
Sample leakage9 to 12%2 to 4%
RCPA reliability72%94%
Prescription lift attributable to verified coverage--4 to 7% revenue impact
Platform cost (annual)--₹4 to 7 Cr
Net P&L impact (Year 1)--+₹35 to 55 Cr

Legacy SFA vs FEI: the architectural shift

Legacy SFA / MR reporting stack

DCR self-submission, MTP planning, GPS check-in, expense tracking, manager review. Verification gaps absorbed as activity noise. Visit adherence at 30 to 40% reality vs 88 to 96% reported. Compliance evidence inconsistent. Sample reconciliation quarterly.

FEI execution stack

9-layer verification, sensor cross-check, face match, RCPA OTP, sample chain of custody, prescription correlation, UCPMP-aligned audit trail, BRSR Core ready retention. Visit adherence rises to 88 to 94% verified. Compliance audit-grade. Sample leakage drops below 4%.

In Indian pharma, the question is no longer how many calls were made. The question is whether the planned doctors were actually covered, whether the conversation actually happened, and whether the field investment is producing prescription lift in the territories that matter.

90-day pharma FEI rollout playbook

PhaseDurationOutcome
Pilot scope and division selectionDays 1 to 10One therapy team or one zone selected, KPIs locked
MR onboarding and trainingDays 11 to 25Field force trained on workflow, dashboards live for managers
First verified DCRs flowDays 26 to 40Baseline coverage gap quantified, ghost call patterns surface
RCPA verification activationDays 41 to 55Chemist OTP integration, audit reliability rises
Sample reconciliation integrationDays 56 to 70Per-MR sample balance visible, leakage quantified
Prescription correlation activatedDays 71 to 85Doctor-level call-to-Rx data emerges
Closeout assessment shared with leadershipDays 86 to 90Side-by-side reported vs verified review with CXO
Roll-out planning for full field forceDay 90 onwardRoadmap to 70 to 95% MR coverage in next 6 months

CFO scorecard for pharma finance heads

CFO questionPre-FEI answerPost-FEI answer
What is our verified field execution rate?UnknownQuantified per division, per region
What is our annual field force productivity leak?EstimatedQuantified in rupees
Can we substantiate sample distribution to auditors?PartialPer-pack chain of custody
What is our UCPMP audit readiness?Self-attestationIndependently verified evidence
Can we defend MR expense reimbursements?Receipt-basedReceipt plus verified visit linkage
How do we measure ROI per MR?Sales outputVerified coverage to Rx-lift coefficient
What is our exposure on territory mis-allocation?UnknownQuarterly rebalancing data
BRSR Core value chain readinessNone7-year audit trail aligned

Year-on-year trajectory under FEI

MetricBaselineYear 1Year 3
MTP verified adherence62 to 78%84 to 90%92 to 96%
A-grade doctor coverage64 to 76%85 to 92%94 to 97%
Productive call rate52 to 68%72 to 80%82 to 88%
Sample leakage9 to 12%3 to 5%1 to 2%
MR productive selling time3.5 to 4.5 hrs5.5 to 6 hrs6 to 6.5 hrs
MR attrition28 to 42%20 to 28%16 to 22%
Field force ROI2.2 to 3.5x3.2 to 4.5x4.5 to 6x
Compliance audit findings4 to 7 open1 to 2 open0 open
pharma field force playbook
FAQ

Frequently Asked Questions

Glossary
Field Execution Intelligence (FEI)The category of platforms producing verified execution data for India's pharma field force. The 5-layer operating standard for accountable pharma sales operations.
Medical Representative (MR)The field sales force unit in pharma. Visits doctors, chemists, hospitals, and distributors to drive prescription and secondary sales. 600,000+ active MRs in India.
Daily Call Report (DCR)Per-day MR submission detailing doctor and chemist visits, samples distributed, POB taken, and outcomes. The core unit of pharma field reporting.
Monthly Tour Plan (MTP)Forward-looking MR plan covering daily and weekly coverage. MTP adherence is a primary SFE KPI.
RCPA (Retail Chemist Prescription Audit)MR-conducted audit of prescription patterns at chemist counter to track brand share and competitive activity. Weekly verification critical for territory intelligence.
POB (Prescription Order Booking)Secondary order capture by MR at chemist, routed through distributor. Connects MR activity to secondary sales.
e-detailingTablet-based digital product detailing to doctors. Replaces or supplements visual aids with interactive content and engagement tracking.
UCPMPUniform Code for Pharmaceutical Marketing Practices. India's regulatory framework for ethical pharma marketing including sample distribution and HCP engagement.
CDSCOCentral Drugs Standard Control Organisation. India's national regulator for drug control and pharmaceutical quality.
NPPANational Pharmaceutical Pricing Authority. Oversees price control on scheduled and non-scheduled drugs.
DPCODrug Prices Control Order. Schedules ceiling prices for essential medicines and drugs.
SFE (Sales Force Effectiveness)The discipline of optimising MR productivity, coverage, and prescription impact. The metric system pharma sales operations are organised around.
A, B, C, D doctor classificationStandard prescriber tiering by prescription potential. A-grade doctors are top 10%, B is next 20%, C is next 40%, D is bottom 30%.
First Line Manager (FLM) or Area Business Manager (ABM)Direct manager of 8 to 12 M₹The first-level supervision layer in pharma field force.
Productive call rate (PCR)% of doctor calls resulting in detailing of strategic brand or generating Rx commitment. Quality metric for MR effectiveness.
Sample chain of custodyPer-pack tracking from stock issuance to MR, to doctor drop, with evidence at each transition. Compliance requirement under UCPMP.
Ground TruthWhat actually happened on the ground, independently verified. The reference state pharma FEI moves field forces toward.
Blind TrustLegacy operating standard treating self-reported DCRs as evidence. The structural condition FEI replaces.

See actual field coverage vs reported coverage

Bring one division or one therapy team for a 14-day pilot. We deploy the 5-layer FEI stack passively. You receive a verified DCR audit, territory coverage gap report, and sample reconciliation summary. Free, no setup required for M₹

22–38%

Typical MTP gap

5–9x

Year-1 ROI

14 days

Onboarding time

Written by

G

gOGig Editorial

Editorial Team, gOGig

gOGig Editorial covers platform education, field execution intelligence, and operational transparency for India's physical economy workforce.

Was this article helpful?

Your feedback helps us write better content.

Related Articles

Mobile van campaign routes in Pune: tier-1 areas, tech parks, and tracking guide (2026)

A practical 2026 mobile van campaign planning guide for Pune-focused brand managers, SaaS + edtech + fintech growth leads, real estate launch teams, FMCG sampling campaign heads, retail store opening managers, political + civic communication strategists, and agency planners running branded LED + T-shape + L-shape + canter vans across Pune's IT corridors, education hubs, residential belts, and manufacturing clusters. Built around the city's 6M+ metropolitan population, 5L+ daily IT commuters, route-design economics for IT park morning + evening windows, education hub student-density timing, manufacturing belt night-shift opportunities, top vendor agency landscape, and the 2026 GPS + AI verification stack that turns mobile van deployment into auditable, route-verified, dwell-time-measured advertising.

3 min read

Shop name board installation in Ahmedabad: vendor network, approval process, 2026 guide

A practical 2026 retail branding guide for FMCG brand managers, automobile + electronics dealer marketing teams, pharma + healthcare chains, agri-input companies, and CFOs running shop name board (storefront fascia) programs across Ahmedabad's ~60-80,000 retail and dealer outlets. Built around AMC (Ahmedabad Municipal Corporation) permission framework + Advision AMC outdoor licensing process, the city's vendor ecosystem from acrylic fabricators to channel letter manufacturers, the 3-phase workflow (Survey → Reiki → Installation) that turns scattered WhatsApp-photo chaos into structured retail branding, and the per-format pricing reality across Ahmedabad's 9 commercial zones.

3 min read

Bus branding in Mumbai: BEST fleet routes, costs, and real-time tracking (2026)

A practical 2026 media planning guide for Mumbai-focused BFSI marketing heads, premium real estate launches, FMCG and OTT brand managers, government civic-campaign teams, airline + travel marketers, and OOH agency planners running BEST bus branding campaigns across India's most valuable transit network. Built around BEST's current 2,911-bus fleet (transitioning to 8,000 electric by 2027), zone-wise route economics, format-specific pricing (full wrap, super king/queen, panel, interior), the 50-strong electric double-decker premium inventory, top vendor agency landscape, and the 2026 GPS + AI + real-time tracking stack that turns large BEST campaigns into auditable, route-verified advertising.

3 min read
← Back to all posts